Jacobsen A, Siebler J, Grützmann R, Stürzl M, Naschberger E. Blood vessel-targeted therapy in colorectal cancer: current strategies and future perspectives. Cancers (Basel). 2024 Feb 22;16(5):890. doi: 10.3390/cancers16050890.
Schulz-Kuhnt A, Rühle K, Javidmehr A, Döbrönti M, Biwank J, Knittel S, Neidlinger P, Leupold J, Liu LJ, Dedden M, Taudte RV, Gessner A, Fromm MF, Mielenz D, Kreiss L, Waldner MJ, Schürmann S, Friedrich O, Dietel B, López-Posadas R, Plattner C; TRR241 IBDome Consortium*; Zundler S, Becker C, Atreya R, Neurath MF, Atreya I. ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo. Gut. 2024 Mar 7;73(4):601-612. doi: 10.1136/gutjnl-2023-330543.
*M. Stürzl is a member of the IBDome Consortium
Naschberger E, Fuchs M, Dickel N, Kunz M, Popp B, Anchang CG, Demmler R, Lyu Y, Uebe S, Ekici AB, Geppert CI, Hartmann A, Flierl C, Petter K, Gass T, Völkl S, Scharl M, Ramming A, Günther C, Merkel S, Schellerer VS, Stürzl M. Tumor microenvironment-dependent epigenetic imprinting in the vasculature predicts colon cancer outcome. Cancer Commun (Lond). 2023 Nov;43(11):1280-1285. doi: 10.1002/cac2.12489. Epub 2023 Oct 19.
Huang J, Demmler R, Mohamed Abdou M, Thoma OM, Weigmann B, Waldner MJ, Stürzl M, Naschberger E. EXPRESS: Rapid qPCR-based quantitative immune cell phenotyping in mouse tissues. J Investig Med. 2024 Jan;72(1):47-56. doi: 10.1177/10815589231210497. Epub 2023 Nov 12.
Thoma OM, Naschberger E, Kubánková M, Larafa I, Kramer V, Menchicchi B, Merkel S, Britzen-Laurent N, Jefremow A, Grützmann R, Koop K, Neufert C, Atreya R, Guck J, Stürzl M, Neurath MF, Waldner MJ. p21 prevents the exhaustion of CD4+ T cells within the antitumor immune response against colorectal cancer. Gastroenterology. 2024 Feb;166(2):284-297.e11. doi: 10.1053/j.gastro.2023.09.017. Epub 2023 Sep 19.
Naschberger E, Flierl C, Huang J, Erkert L, Gamez-Belmonte R, Gonzalez-Acera M, Bober M, Mehnert M, Becker C, Schellerer VS, Britzen-Laurent N, Stürzl M. Analysis of the interferon-γ-induced secretome of intestinal endothelial cells: putativem impact on epithelial barrier dysfunction in IBD. Front. Cell Dev. Biol. 2023 Aug 14;11:1213383. doi: 10.3389/fcell.2023.1213383. eCollection 2023.
Bénard A, Mittelstädt A, Klösch B, Glanz K, Müller J, Schoen J, Nüse B, Brunner M, Naschberger E, Stürzl M, Mattner J, Muñoz LE, Sohn K, Grützmann R, Weber GF. IL-3 orchestrates ulcerative colitis pathogenesis by controlling the development and the recruitment of splenic reservoir neutrophils. Cell Rep. 2023 Jun 27;42(6):112637. doi: 10.1016/j.celrep.2023.112637. Epub 2023 Jun 8.
Schulze LL, Becker E, Dedden M, Liu LJ, van Passen C, Mohamed Abdou M, Müller TM, Wiendl M, Ullrich KA, Atreya I, Leppkes M, Ekici AB, Kirchner P, Stürzl M, Sexton D, Palliser D, Atreya R, Siegmund B; TRR241 IBDome consortium*; Neurath MF, Zundler S. Differential effects of ontamalimab versus vedolizumab on immune cell trafficking in intestinal inflammation and IBD. J Crohns Colitis. 2023 Nov 24;17(11):1817-1832. doi: 10.1093/ecco-jcc/jjad088.
*M. Stürzl is a member of the IBDome Consortium
Reimann TM, Müdsam C, Schachtler C, Ince S, Sticht H, Herrmann C, Stürzl M, Kost B. The large GTPase AtGBPL3 links nuclear envelope formation and morphogenesis to transcriptional repression. Nat Plants. 2023 May;9(5):766-784. doi: 10.1038/s41477-023-01400-5. Epub 2023 Apr 24.
Britzen-Laurent N, Weidinger C, Stürzl M. Contribution of blood vessel activation, remodeling and barrier function to inflammatory bowel diseases. Int. J. Mol. Sci. 2023, 24(6), 5517; https://doi.org/10.3390/ijms24065517. Review.
Wang H, Stehr AM, Singh J, Zlatar L, Hartmann A, Evert K, Naschberger E, von Stillfried S, Boor P, Muñoz LE, Knopf J, Stürzl M, Herrmann M. Anti-DNA-IgM favors the detection of NET-associated extracellular DNA. Int J Mol Sci. 2023 Feb 17;24(4):4101. doi: 10.3390/ijms24044101.
Singh J, Boettcher M, Dölling M, Heuer A, Hohberger B, Leppkes M, Naschberger E, Schapher M, Schauer C, Schoen J, Stürzl M, Vitkov L, Wang H, Zlatar L, Schett GA, Pisetsky DS, Liu ML, Herrmann M, Knopf J. Moonlighting chromatin: when DNA escapes nuclear control. Cell Death Differ. 2023 Apr;30(4):861-875. doi: 10.1038/s41418-023-01124-1. Epub 2023 Feb 8.
Fang Q, Stehr AM, Naschberger E, Knopf J, Herrmann M, Stürzl M. No NETs no TIME: Crosstalk between neutrophil extracellular traps and the tumor immune microenvironment. Front Immunol. 2022 Dec 23;13:1075260. doi: 10.3389/fimmu.2022.1075260. eCollection 2022. Review.
Krug J, Rodrian G, Petter K, Yang H, Khoziainova S, Guo W, Bénard A, Merkel S, Gellert S, Maschauer S, Spermann M, Waldner M, Bailey P, Pilarsky C, Liebl A, Tripal P, Christoph J, Naschberger E, Croner R, Schellerer VS, Becker C, Hartmann A, Tüting T, Prante O, Grützmann R, Grivennikov SI, Stürzl M, Britzen-Laurent N. N-glycosylation regulates intrinsic IFN-γ resistance in colorectal cancer: implications for immunotherapy. Gastroenterology. 2023 Mar;164(3):392-406.e5. doi: 10.1053/j.gastro.2022.11.018. Epub 2022 Nov 17.PMID: 36402190
Gamez-Belmonte R, Mahapatro M, Erkert L, Gonzalez-Acera M, Naschberger E, Yu Y, Tena-Garitaonaindia M, Patankar JV, Wagner Y, Podstawa E, Schödel L, Bubeck M, Neurath MF, Stürzl M, Becker C. Epithelial presenilin-1 drives colorectal tumour growth by controlling EGFR-COX2 signalling. Gut. 2023 Jun;72(6):1155-1166. doi: 10.1136/gutjnl-2022-327323. Epub 2022 Oct 19.
Ammon A, Mellenthin L, Emmerich C, Naschberger E, Stürzl M, Mackensen A, Müller F. Reduced cytotoxicity by mutation of lysine 590 of Pseudomonas exotoxin can be restored in an optimized, lysine-free immunotoxin. Immunother Adv. 2022 Feb 21;2(1):ltac007. doi: 10.1093/immadv/ltac007. eCollection 2022.
Busenhart P, Montalban-Arques A, Katkeviciute E, Morsy Y, Van Passen C, Hering L, Atrott K, Lang S, Garzon JFG, Naschberger E, Hartmann A, Rogler G, Stürzl M, Spalinger MR, Scharl M. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. J Immunother Cancer. 2022 Feb;10(2):e003465. doi: 10.1136/jitc-2021-003465.
Yu YQ, Thonn V, Patankar JV, Thoma OM, Waldner M, Zielinska M, Bao LL, Gonzalez-Acera M, Wallmüller S, Engel FB, Stürzl M, Neurath MF, Liebing E, Becker C. SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth. Cell Death Dis. 2022 Jan 12;13(1):52. doi: 10.1038/s41419-021-04483-0.
Stehr AM, Wang G, Demmler R, Stemmler MP, Krug J, Tripal P, Schmid B, Geppert CI, Hartmann A, Muñoz LE, Schoen J, Völkl S, Merkel S, Becker C, Schett G, Grützmann R, Naschberger E, Herrmann M, Stürzl M. Neutrophil extracellular traps drive epithelial-mesenchymal transition of human colon cancer. Inflamm Bowel Dis. 2021 Aug 19;27(9):1491-1502. doi: 10.1093/ibd/izaa346.
Stürzl M, Kunz M, Krug SM, Naschberger E. Angiocrine regulation of epithelial barrier integrity in inflammatory bowel disease. Front Med (Lausanne). 2021 Aug 2;8:643607. doi: 10.3389/fmed.2021.643607. eCollection 2021. Review.
Ackermann M, Anders HJ, Bilyy R, Bowlin GL, Daniel C, De Lorenzo R, Egeblad M, Henneck T, Hidalgo A, Hoffmann M, Hohberger B, Kanthi Y, Kaplan MJ, Knight JS, Knopf J, Kolaczkowska E, Kubes P, Leppkes M, Mahajan A, Manfredi AA, Maueröder C, Maugeri N, Mitroulis I, Muñoz LE, Narasaraju T, Naschberger E, Neeli I, Ng LG, Radic MZ, Ritis K, Rovere-Querini P, Schapher M, Schauer C, Simon HU, Singh J, Skendros P, Stark K, Stürzl M, van der Vlag J, Vandenabeele P, Vitkov L, von Köckritz-Blickwede M, Yanginlar C, Yousefi S, Zarbock A, Schett G, Herrmann M. Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death Differ. 2021 Nov;28(11):3125-3139. doi: 10.1038/s41418-021-00805-z. Epub 2021 May 24.
Regensburger D, Tenkerian C, Pürzer V, Schmid B, Wohlfahrt T, Stolzer I, López-Posadas R, Günther C, Waldner MJ, Becker C, Sticht H, Petter K, Flierl C, Gass T, Thoenissen T, Geppert C, Britzen-Laurent N, Méniel VS, Ramming A, Stürzl M, Naschberger E. Matricellular protein SPARCL1 regulates blood vessel integrity and antagonizes inflammatory bowel disease. Inflamm Bowel Dis. 2021 Aug 19;27(9):1491-1502. doi: 10.1093/ibd/izaa346.
Katkeviciute E, Hering L, Montalban-Arques A, Busenhart P, Schwarzfischer M, Manzini R, Conde J, Atrott K, Lang S, Rogler G, Naschberger E, Schellerer VS, Stürzl M, Rickenbacher A, Turina M, Weber A, Leibl S, Leventhal GE, Levesque M, Boyman O, Scharl M, Spalinger MR. Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development. J Clin Invest. 2021 Jan 4;131(1):e140281. doi: 10.1172/JCI140281.